HPV testing alone as a test of cure after treatment with cervical loop excision: a retrospective register-based cohort study.

Infect Agent Cancer

Department of Women's and Children's Health, Uppsala University, Akademiska sjukhuset, Uppsala, 751 85, Sweden.

Published: August 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Women treated with cervical loop electrosurgical excision procedure require follow-up to detect residual or recurrent HSIL+, defined as high-grade squamous intraepithelial lesions, adenocarcinoma in situ or cervical cancer. Currently, co-testing with cytology and human papillomavirus (HPV) analysis is usually recommended. This study investigates whether HPV testing alone is comparable to co-testing in detecting HSIL + up to three years after treatment. Recurrence rates of HSIL + are also presented, with follow-up extending up to 18 years.

Methods: This retrospective cohort study included all 3,540 women treated with a cervical excision in Uppsala County between 1 January 2005 and 31 December 2019. Women with cancer identified in the cone biopsy were excluded. The main outcome was HSIL + detected within three years of follow-up. Sensitivity, specificity and negative predictive value were calculated for the 1,938 women who had a co-testing result as part of their test of cure. Thus, the analysis for the main outcome could finally be performed on 1,938 out of the total number of 3,540 women. Additionally, long-term data on recurrence and time to HSIL+, along with a separate analysis of results prior to cervical cancer diagnosis, were collected for the whole cohort of 3,399 women.

Results: The sensitivity and negative predictive value for detecting HSIL + were 69% and 97% for HPV alone, and 74% and 98% for co-testing, respectively. These differences were not statistically significant. Specificity was higher for HPV alone than for co-testing. The negative predictive value of HPV testing for excluding cervical cancer (n = 5) within three years was 100%. Recurrence rate of HSIL + in the three-year follow up was 8%, and the total recurrence rate of HSIL + with a mean follow-up of nine years was 10%. Mean time to recurrence was 28 months. None of 19 cervical cancer cases identified in the long-term follow-up had a co-testing result showing negative HPV but positive cytology.

Conclusions: HPV testing alone, as a single test, is comparable to co-testing in detecting HSIL + up to three years after treatment independently of margin status, and demonstrates a higher specificity. Cytology plays a very limited role in the test of cure analysis and could therefore be omitted.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12392528PMC
http://dx.doi.org/10.1186/s13027-025-00690-yDOI Listing

Publication Analysis

Top Keywords

hpv testing
16
cervical cancer
16
three years
16
test cure
12
negative predictive
12
hpv
8
cervical loop
8
cohort study
8
women treated
8
treated cervical
8

Similar Publications

Purpose: Early detection of HPV-associated oropharyngeal cancer (HPV+OPSCC), the most common HPV cancer in the United States, could reduce disease-related morbidity and mortality, yet currently, there are no early detection tests. Circulating tumor HPV DNA (ctHPVDNA) is a sensitive and specific biomarker for HPV+OPSCC at diagnosis. It is unknown if ctHPVDNA is detectable prior to diagnosis, and thus it's potential as an early detection test.

View Article and Find Full Text PDF

Persistent high-risk human papillomavirus (hHPV) infection, especially HPV-16, plays a central role in the development of high-grade squamous intraepithelial lesions (HSIL). This study aimed to evaluate the performance of co-testing (cytology and hHPV detection) in a real-world cohort of men who have sex with men (MSM) and transgender women (TW) living with HIV. We conducted a prospective study (2017-2023) at a tertiary care center in Spain.

View Article and Find Full Text PDF

Cervical cancer remains the leading cause of cancer death among women in sub-Saharan Africa and is more severe in high HIV-burdened countries due to persistent high-risk human papillomavirus (hrHPV). In 2021, the World Health Organization recommended primary hrHPV testing for cervical cancer screening; however, optimal triage strategies following positive hrHPV tests remain unclear. We conducted a prospective cost analysis of triage methods for positive hrHPV results among women living with and without HIV in Gaborone, Botswana.

View Article and Find Full Text PDF

A Scoping Review of Women with Physical Disabilities and Cervical Cancer Screening.

J Womens Health (Larchmt)

September 2025

Department of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, Michigan, USA.

Women with physical disabilities (WWPDs) have lower screening rates for cervical cancer than the general population globally. This scoping review aims to define the type of studies and content of studies currently available to promote cervical cancer screening among WWPDs. It seeks to clarify the type of disabilities WWPDs have that lead to the poorest participation in cervical cancer screening and highlight how health care systems can address the disclosed gaps.

View Article and Find Full Text PDF

Background Cervical cancer remains a significant public health concern in India. The objective of this study was to compare cytological abnormalities and HPV positivity rates between pregnant and non-pregnant women. Materials and methods This prospective observational study was performed at a tertiary care center in North India.

View Article and Find Full Text PDF